Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04266340
Other study ID # 20180341
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 13, 2020
Est. completion date December 1, 2021

Study information

Verified date May 2022
Source Eye & ENT Hospital of Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators studied the effects of intranasal dexmedetomidine compared with oral midazolam with different doses for premedication in children. One hundred and twenty children aged between 2 and 12 years were randomly allocated to one of four groups:2.5µg/kg intranasal dexmedetomidine group ; 0.5mg/kg oral midazolam group;0.05 mg/kg intravenous injection midazolam group; no premedication group. Sedation levels 10, 20, and 30min after premedication were evaluated using a 5-point sedation scale. A 4-point emotional state score was used to evaluate participators when they were separated from their parents and their response to intravenous cannulation or facemask application. Agitation scores (Pediatric Anesthe-sia Emergence Delirium [PAED] scale) and POV were assessed in the postanesthetic care unit (PACU).Times to endotracheal tube or laryngeal mask airway removal, discharge from the PACU and patients' satisfaction degree were also assessed.


Recruitment information / eligibility

Status Completed
Enrollment 320
Est. completion date December 1, 2021
Est. primary completion date November 15, 2021
Accepts healthy volunteers No
Gender All
Age group 2 Years to 12 Years
Eligibility Inclusion Criteria: - Exclusion Criteria: - a recent history of upper respiratory tract infection, a known allergy to dexmedetomidine or midazolam, inability to understand the consent process or parental refusal.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
dexmedetomidine
2.5µg/kg intranasal dexmedetomidine group
midazolam
0.5mg/kg oral midazolam
midazolam
0.05mg/kg intravenous injection midazolam
Saline
no premedication

Locations

Country Name City State
China Department of Anesthesiology, The Eye, Ear, Nose and Throat Hospital of Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Eye & ENT Hospital of Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sedation Rarely awake, needs shaking or shouting to wake up
Asleep, eyes closed, wakes up when called softly or lightly touched
Sleepy but eyes open spontaneously
Awake
Agitated
10 minutes after premedication
Primary Sedation Rarely awake, needs shaking or shouting to wake up
Asleep, eyes closed, wakes up when called softly or lightly touched
Sleepy but eyes open spontaneously
Awake
Agitated
20 minutes after premedication
Primary Sedation Rarely awake, needs shaking or shouting to wake up
Asleep, eyes closed, wakes up when called softly or lightly touched
Sleepy but eyes open spontaneously
Awake
Agitated
30 minutes after premedication
Primary Emotional state Calm
Apprehensive, not smiling, tentative behaviour, withdrawn
Crying
Thrashing, crying with movement of arms and legs, resisting
0 minutes after they were separated from their parents
Primary Emotional state Calm
Apprehensive, not smiling, tentative behaviour, withdrawn
Crying
Thrashing, crying with movement of arms and legs, resisting
0 minutes after intravenous cannulation
Primary Emotional state Calm
Apprehensive, not smiling, tentative behaviour, withdrawn
Crying
Thrashing, crying with movement of arms and legs, resisting
0 minutes after facemask application
See also
  Status Clinical Trial Phase
Completed NCT02525991 - Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting Phase 4
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Completed NCT01976754 - Safety Study of Dexmedetomidine in Septic Patients N/A
Completed NCT01217541 - Collaboration Between Department of Old Age Psychiatry and Nursing Homes N/A
Withdrawn NCT00786318 - Ziprasidone vs Standard Therapy for Agitated Patients in the ED Phase 4
Not yet recruiting NCT05974527 - Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department Phase 4
Not yet recruiting NCT05522647 - Detection of Risk Behaviors: Pilot Observational Study With Bedridden and Agitated Patients.
Recruiting NCT02590744 - Effects of Preoperative Using of Eye Patches on Prevention of Emergence Agitation After Cataract Surgery N/A
Recruiting NCT02164773 - Addition of Magnesium Sulfate to Caudal to Prevent Postoperative Emergence Agitation. Phase 4
Completed NCT01524367 - Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery Phase 4
Completed NCT01501123 - Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient N/A
Completed NCT01021696 - Pain in Patients With Dementia and Behavioural Disturbances Phase 2/Phase 3
Recruiting NCT05397639 - Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Phase 3
Terminated NCT03044249 - A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression Phase 2
Completed NCT05165914 - Midazolam Effect on Agitation Postnasal Surgery N/A
Completed NCT04010305 - Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia Phase 1
Completed NCT02720705 - Transbucal Dexmedetomidine for Prevention of Sevoflurane Emergence Agitation in Pre-school Children Phase 2/Phase 3
Completed NCT02428283 - Scalp Nerve Block on Emergence Agitation Phase 4
Completed NCT00457366 - A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room Phase 4
Terminated NCT00315900 - Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia Phase 3